Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
← catalyst calendarSponsored by Kymera Therapeutics, Inc. (industry) · KYMR — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
56actual
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-05-19 | actual | When the study began enrolling |
| Primary completion | 2025-03-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-03 | actual | The whole study's end, after follow-up |
| First posted | 2022-02-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non Hodgkin Lymphoma (NHL)
- Peripheral T-cell Lymphoma (PTCL)
- Cutaneous T-Cell Lymphoma (CTCL)
- Large Granular Lymphocytic Leukemia (LGL-L)
- T-cell Prolymphocytic Leukemia (T-PLL)
- Solid Tumors
Intervention
- Drug: KT-333
Primary outcomes
what the primary-completion date above is the date OFSafety
measured Safety will be assessed from the time ICF signature through 30 days post dose or prior to start of a new anticancer therapy
Safety
measured Safety will be assessed from the time ICF signature through 30 days post dose or prior to start of a new anticancer therapy
Safety
measured Safety will be assessed from the time ICF signature through 30 days post dose or prior to start of a new anticancer therapy
Maximum Tolerated Dose (MTD)
measured Within the first 28 days of treatment
Dose Limiting Toxicities (DLTs)
measured Within the first 28days of treatment
Permalink · KYMR's whole pipeline · Catalyst calendar · Every registered study · What changed